Corporate Overview

Corporate Overview

Founded in 1996, China Pioneer Pharma Holdings Limited (the "Company")is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China. We constantly introduce products embedded with technologies that represent international advanced level into Chinese market. In 5 November 2013, the Company was successfully listed on the main board of the Stock Exchange of Hong Kong Limited with stock code HK.01345.
As a domestic company with global vision, the Company has established long-term and stable cooperation with a number of renowned international suppliers. The network of overseas suppliers lays the foundation of the sustainable development of the Company through comprehensive and effective product introduction and supplier cooperation. The Company has built up a sales system covering whole China and most Southeast Asia countries and regions. With long-term efforts, the Company has created a unique brand foundation.
Currently, the Company has established long-term stable cooperative relation ship with Alcon of USA, Alfa Wassermann of Italy, Aenova of Germany, Orion of Finland, Polichem of Switzerland, Covex S.A. of Spain, Qualimed of Germany and NovaBay of USA.
The Company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, respiratory, gastroenterology, immunology and other therapeutic areas, and medical devices covering four medical specialties, including ophthalmology odontology, wound care and etc. At the same time, the Company endeavors to uplift the market value of these brands.
In the aspect of building marketing and promotion team in China, the Company has built up a national sales system, and has established stable cooperative relationship with 500 nation-wide distributors. The nation-wide network of the Company covered over 29,000 hospitals and medical institutions and over 105,000 pharmacies across China as of 30 June 2016.
In addition, the company is dedicated to gradually implement globalization strategy, and has begun to explore Southeast Asia markets and carry out strategic investment in overseas suppliers. For instance, the Company has purchased equities in NovaBay Pharmaceuticals, a US-based biopharmaceutical company; Q3, a Ireland-based company specialized in the development and the design of medical devices for the treatment of vascular diseases, and Covex S.A., a Spain-based API supplier. Through these investments, the Company is not only deepening the cooperation with overseas suppliers, but also gradually realizing the goal of internationalization.
Looking forword, with rapid development of China's pharmaceutical industry, through an open-minded attitude, prospective new product introduction capability, accurate product marketing strategy, comprehensive marketing network and effective management system, we will carry out merge and acquisition, adapt to the change of medicine industry, seize the opportunity, take roots in the market, and realize the long term sustainable development.